{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:37:15Z","timestamp":1786988235782,"version":"build-2736575974"},"reference-count":83,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI141439"],"award-info":[{"award-number":["R01AI141439"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>\n                    Cryptococcosis is a major health threat among immunocompromised individuals, resulting in life-threatening consequences secondary to brain invasion. The limited treatment options and the increased incidence of treatment failure and relapses urge the need for more effective therapies. In this study, we investigated the therapeutic potential of nitroxoline (NTX) in treating cryptococcal infection. NTX exhibited potent fungicidal activity against\n                    <jats:italic>Cryptococcus neoformans\/gattii<\/jats:italic>\n                    clinical isolates, with an MIC\n                    <jats:sub>90<\/jats:sub>\n                    of 1 \u00b5g\/mL. In addition, NTX substantially inhibits the main virulence traits of cryptococcal cells, including the polysaccharide capsule, melanin production, and the urease enzyme, which are crucial for the infection progression. In exploring the potential mechanism of action, our results revealed the relationship between the metal-chelating properties of the NTX scaffold and its antifungal activity. Interfering metal chelation, either through structural modification or exogenous supplementation with varied divalent cations, significantly reduced the antifungal and anti-virulence activities of NTX. Given its potential therapeutic role, we evaluated the interaction between NTX and the clinically used antifungals amphotericin B, flucytosine and fluconazole. Additionally, we investigated the tendency of cryptococcal cells to develop resistance following repeated exposure to NTX, as well as its efficacy in the\n                    <jats:italic>Caenorhabditis elegans<\/jats:italic>\n                    nematode model of cryptococcal infection. Notably, cryptococcal cells exhibited consistent susceptibility to NTX upon repeated exposure to a subinhibitory concentration. In the\n                    <jats:italic>C. elegans<\/jats:italic>\n                    model, NTX significantly reduced the fungal burden of the infected worms, achieving a 2-log10 reduction, and consistently enhanced their survival compared to untreated group. These findings highlight the potential role of the NTX scaffold in combating cryptococcal infection that warrants further investigation.\n                  <\/jats:p>","DOI":"10.1371\/journal.pntd.0014627","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:23:42Z","timestamp":1786987422000},"page":"e0014627","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the therapeutic potential of the antibacterial drug nitroxoline in combating cryptococcal infection"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0632-3747","authenticated-orcid":true,"given":"Nour M.","family":"Alkashef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-0458","authenticated-orcid":true,"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"1","key":"pntd.0014627.ref001","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.idc.2015.10.006","article-title":"Cryptococcosis","volume":"30","author":"EK Maziarz","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"pntd.0014627.ref002","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10010013","article-title":"Recent Advances in Cryptococcus and Cryptococcosis","volume":"10","author":"C Firacative","year":"2021","journal-title":"Microorganisms"},{"issue":"4","key":"pntd.0014627.ref003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1286-4579(99)80025-2","article-title":"Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms","volume":"1","author":"ML Rodrigues","year":"1999","journal-title":"Microbes Infect"},{"issue":"7","key":"pntd.0014627.ref004","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760180057","article-title":"Cryptococcal pathogenic mechanisms: a dangerous trip from the environment to the brain","volume":"113","author":"SK Esher","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"12","key":"pntd.0014627.ref005","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","volume":"22","author":"R Rajasingham","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pntd.0014627.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"DW Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pntd.0014627.ref007","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41579-021-00511-0","article-title":"Treatment strategies for cryptococcal infection: challenges, advances and future outlook","volume":"19","author":"KR Iyer","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"pntd.0014627.ref008","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/AAC.00295-09","article-title":"Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence","volume":"53","author":"E Sionov","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pntd.0014627.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00731-4","article-title":"Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM","volume":"24","author":"CC Chang","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pntd.0014627.ref010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america","volume":"50","author":"JR Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pntd.0014627.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30493-6","article-title":"Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries","volume":"19","author":"A Loyse","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pntd.0014627.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067311","article-title":"A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi","volume":"8","author":"C Rothe","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"pntd.0014627.ref013","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/593194","article-title":"Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda","volume":"47","author":"N Longley","year":"2008","journal-title":"Clin Infect Dis"},{"key":"pntd.0014627.ref014","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4761","article-title":"Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis","volume":"6","author":"M Truong","year":"2018","journal-title":"PeerJ"},{"issue":"2","key":"pntd.0014627.ref015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/EC.00314-12","article-title":"A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis","volume":"12","author":"A Butts","year":"2013","journal-title":"Eukaryot Cell"},{"issue":"12","key":"pntd.0014627.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0013837","article-title":"In vitro and in vivo efficacy of the antimycobacterial molecule SQ109 against the human pathogenic fungus, Cryptococcus neoformans","volume":"19","author":"NM Alkashef","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0014627.ref017","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1128\/AAC.03946-14","article-title":"In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany","volume":"58","author":"M Kresken","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pntd.0014627.ref018","first-page":"339","article-title":"Nitroxoline: treatment and prevention of urinary tract infections from the urologist\u2019s perspective","volume":"77","author":"W Krajewski","year":"2024","journal-title":"Cent European J Urol"},{"key":"pntd.0014627.ref019","doi-asserted-by":"crossref","first-page":"104884","DOI":"10.1016\/j.antiviral.2020.104884","article-title":"Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening","volume":"182","author":"Z-R Zhang","year":"2020","journal-title":"Antiviral Res"},{"issue":"5","key":"pntd.0014627.ref020","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02051-18","article-title":"Functional assessment of 2,177 U.S. and international drugs identifies the quinoline nitroxoline as a potent amoebicidal agent against the pathogen Balamuthia mandrillaris","volume":"9","author":"MT Laurie","year":"2018","journal-title":"mBio"},{"issue":"10","key":"pntd.0014627.ref021","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1128\/AAC.00325-16","article-title":"8-hydroxyquinolines are boosting agents of copper-related toxicity in Mycobacterium tuberculosis","volume":"60","author":"S Shah","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0014627.ref022","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1038\/s41467-025-58730-5","article-title":"Uncovering nitroxoline activity spectrum, mode of action and resistance across Gram-negative bacteria","volume":"16","author":"E Cacace","year":"2025","journal-title":"Nat Commun"},{"key":"pntd.0014627.ref023","doi-asserted-by":"crossref","first-page":"906097","DOI":"10.3389\/fphar.2022.906097","article-title":"In vitro activity of repurposed nitroxoline against clinically isolated mycobacteria including multidrug-resistant Mycobacterium tuberculosis","volume":"13","author":"AM Hoffmann","year":"2022","journal-title":"Front Pharmacol"},{"issue":"11","key":"pntd.0014627.ref024","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/jac\/dky255","article-title":"Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline","volume":"73","author":"RA Wijma","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0014627.ref025","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard","author":"CALS Institute","year":"2008","edition":"3"},{"issue":"8","key":"pntd.0014627.ref026","article-title":"Miltefosine has a postantifungal effect and induces apoptosis in Cryptococcus yeasts","volume":"62","author":"CDC Spadari","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pntd.0014627.ref027","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1128\/AAC.00212-12","article-title":"The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections","volume":"56","author":"B Zhai","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pntd.0014627.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308216","article-title":"Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B\u2019s antifungal efficacy in cryptococcosis","volume":"19","author":"NM Alkashef","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"pntd.0014627.ref029","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41467-023-36552-7","article-title":"Reciprocal modulation of ammonia and melanin production has implications for cryptococcal virulence","volume":"14","author":"RP Baker","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"pntd.0014627.ref030","article-title":"Cryptococcus neoformans urease affects the outcome of intracellular pathogenesis by modulating phagolysosomal pH","volume":"14","author":"MS Fu","year":"2018","journal-title":"PLoS Pathog"},{"issue":"1","key":"pntd.0014627.ref031","article-title":"Pharmacological inhibition of pigmentation in Cryptococcus","volume":"19","author":"ACG Zimbres","year":"2019","journal-title":"FEMS Yeast Res"},{"key":"pntd.0014627.ref032","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-0716-3722-7_17","article-title":"Measuring laccase activity and melanin production in Cryptococcus neoformans.","volume-title":"Cryptococcus neoformans: Methods and Protocols","author":"P Albuquerque","year":"2024"},{"issue":"4","key":"pntd.0014627.ref033","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/jof8040393","article-title":"Faster Cryptococcus melanization increases virulence in experimental and human Cryptococcosis","volume":"8","author":"HR de Sousa","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"pntd.0014627.ref034","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.01423","article-title":"Capsule enlargement in Cryptococcus neoformans is dependent on mitochondrial activity","volume":"8","author":"N Trevijano-Contador","year":"2017","journal-title":"Front Microbiol"},{"issue":"7","key":"pntd.0014627.ref035","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01031-24","article-title":"Brilacidin, a novel antifungal agent against Cryptococcus neoformans","volume":"15","author":"C Diehl","year":"2024","journal-title":"mBio"},{"issue":"6","key":"pntd.0014627.ref036","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/21505594.2015.1038014","article-title":"Histone deacetylases inhibitors effects on Cryptococcus neoformans major virulence phenotypes","volume":"6","author":"FA Brand\u00e3o","year":"2015","journal-title":"Virulence"},{"issue":"7","key":"pntd.0014627.ref037","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1128\/AAC.02316-13","article-title":"Copper complexation screen reveals compounds with potent antibiotic properties against methicillin-resistant Staphylococcus aureus","volume":"58","author":"M Haeili","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0014627.ref038","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1038\/s41467-018-07633-9","article-title":"Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation","volume":"9","author":"W Chang","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"pntd.0014627.ref039","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41564-024-01662-5","article-title":"A dual-targeting antifungal is effective against multidrug-resistant human fungal pathogens","volume":"9","author":"M Zhou","year":"2024","journal-title":"Nat Microbiol"},{"issue":"1","key":"pntd.0014627.ref040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00684-20","article-title":"Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant Candida auris","volume":"65","author":"HE Eldesouky","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"24","key":"pntd.0014627.ref041","doi-asserted-by":"crossref","first-page":"15675","DOI":"10.1073\/pnas.232568599","article-title":"Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis","volume":"99","author":"E Mylonakis","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"pntd.0014627.ref042","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/infdis\/jit164","article-title":"Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients","volume":"208","author":"L O\u2019Connor","year":"2013","journal-title":"J Infect Dis"},{"issue":"6","key":"pntd.0014627.ref043","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"R Bellmann","year":"2017","journal-title":"Infection"},{"key":"pntd.0014627.ref044","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.fgb.2014.10.003","article-title":"Cryptococcosis diagnosis and treatment: What do we know now","volume":"78","author":"JR Perfect","year":"2015","journal-title":"Fungal Genet Biol"},{"issue":"6","key":"pntd.0014627.ref045","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02575-19","article-title":"Fluconazole monotherapy is a suboptimal option for initial treatment of Cryptococcal meningitis because of emergence of resistance","volume":"10","author":"W Hope","year":"2019","journal-title":"mBio"},{"issue":"4","key":"pntd.0014627.ref046","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"TI Oprea","year":"2012","journal-title":"AAPS J"},{"issue":"4","key":"pntd.0014627.ref047","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/jof5040097","article-title":"Antifungal drugs: special problems treating central nervous system infections","volume":"5","author":"ED Ashley","year":"2019","journal-title":"J Fungi (Basel)"},{"issue":"11","key":"pntd.0014627.ref048","doi-asserted-by":"crossref","DOI":"10.1111\/myc.70131","article-title":"In vitro activity of nitroxoline (5-nitro-8-hydroxyquinoline) against Aspergillus species","volume":"68","author":"A Hoffmann","year":"2025","journal-title":"Mycoses"},{"issue":"6","key":"pntd.0014627.ref049","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02265-21","article-title":"In vitro activity of nitroxoline in antifungal-resistant Candida species isolated from the urinary tract","volume":"66","author":"F Fuchs","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pntd.0014627.ref050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.06.035","article-title":"Antifungal activity of nitroxoline against Candida auris isolates","volume":"27","author":"F Fuchs","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"pntd.0014627.ref051","article-title":"Cryptococcal meningitis and anti-virulence therapeutic strategies","volume":"10","author":"K Vu","year":"2019","journal-title":"Front Microbiol"},{"issue":"3","key":"pntd.0014627.ref052","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1128\/IAI.72.3.1693-1699.2004","article-title":"CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence","volume":"72","author":"MC Noverr","year":"2004","journal-title":"Infect Immun"},{"issue":"12","key":"pntd.0014627.ref053","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02155-23","article-title":"Elements of dissemination in cryptococcosis","volume":"15","author":"JM Bednarek","year":"2024","journal-title":"mBio"},{"issue":"5","key":"pntd.0014627.ref054","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0002-9440(10)63734-0","article-title":"Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion","volume":"164","author":"MA Olszewski","year":"2004","journal-title":"Am J Pathol"},{"issue":"3","key":"pntd.0014627.ref055","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00220-13","article-title":"Factors required for activation of urease as a virulence determinant in Cryptococcus neoformans","volume":"4","author":"A Singh","year":"2013","journal-title":"mBio"},{"issue":"3","key":"pntd.0014627.ref056","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.39.3.707","article-title":"Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains","volume":"39","author":"C Pelletier","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pntd.0014627.ref057","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00203-022-03122-2","article-title":"Antimicrobial activity of clioquinol and nitroxoline: a scoping review","volume":"204","author":"R Wykowski","year":"2022","journal-title":"Arch Microbiol"},{"issue":"1","key":"pntd.0014627.ref058","doi-asserted-by":"crossref","first-page":"2294854","DOI":"10.1080\/22221751.2023.2294854","article-title":"Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition","volume":"13","author":"P He","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"10","key":"pntd.0014627.ref059","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1089\/mdr.2020.0037","article-title":"Zinc chelators as carbapenem adjuvants for metallo-\u03b2-lactamase-producing bacteria: in vitro and in vivo evaluation","volume":"26","author":"L Principe","year":"2020","journal-title":"Microb Drug Resist"},{"issue":"1","key":"pntd.0014627.ref060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1574-6968.2009.01619.x","article-title":"A copper-responsive factor gene CUF1 is required for copper induction of laccase in Cryptococcus neoformans","volume":"296","author":"N Jiang","year":"2009","journal-title":"FEMS Microbiol Lett"},{"issue":"1","key":"pntd.0014627.ref061","doi-asserted-by":"crossref","first-page":"101519","DOI":"10.1016\/j.jbc.2021.101519","article-title":"Cryptococcus neoformans melanization incorporates multiple catecholamines to produce polytypic melanin","volume":"298","author":"RP Baker","year":"2022","journal-title":"J Biol Chem"},{"issue":"3","key":"pntd.0014627.ref062","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1172\/JCI30006","article-title":"Role of a CUF1\/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans","volume":"117","author":"SR Waterman","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"pntd.0014627.ref063","article-title":"Fungal-metal interactions: a review of toxicity and homeostasis","volume":"7","author":"JR Robinson","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"12","key":"pntd.0014627.ref064","article-title":"Iron regulation of the major virulence factors in the AIDS-associated pathogen Cryptococcus neoformans","volume":"4","author":"WH Jung","year":"2006","journal-title":"PLoS Biol"},{"issue":"4","key":"pntd.0014627.ref065","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/hep.510290435","article-title":"Determination of the chelatable iron pool of isolated rat hepatocytes by digital fluorescence microscopy using the fluorescent probe, phen green SK","volume":"29","author":"F Petrat","year":"1999","journal-title":"Hepatology"},{"key":"pntd.0014627.ref066","doi-asserted-by":"crossref","first-page":"100578","DOI":"10.1016\/j.ijpddr.2025.100578","article-title":"Nitroxoline evidence amoebicidal activity against Acanthamoeba castellanii through DNA damage and the stress response pathways","volume":"27","author":"L Chen","year":"2025","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"5","key":"pntd.0014627.ref067","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01831-25","article-title":"Nitroxoline exerts potent anti-Aspergillus fumigatus activity by disrupting copper homeostasis and inducing oxidative stress","volume":"70","author":"Y Zhang","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pntd.0014627.ref068","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000848","article-title":"Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes","volume":"6","author":"E Sionov","year":"2010","journal-title":"PLoS Pathog"},{"issue":"4","key":"pntd.0014627.ref069","doi-asserted-by":"crossref","first-page":"101438","DOI":"10.1016\/j.mycmed.2023.101438","article-title":"Fungal diseases in Africa: Closing the gaps in diagnosis and treatment through implementation research and advocacy","volume":"33","author":"F Bongomin","year":"2023","journal-title":"J Mycol Med"},{"key":"pntd.0014627.ref070","doi-asserted-by":"crossref","first-page":"100014","DOI":"10.1016\/j.lanafr.2025.100014","article-title":"Health disparities and the burden of fungal infections in Africa","volume":"4","author":"F Bongomin","year":"2026","journal-title":"Lancet Region Health - Afr"},{"issue":"11","key":"pntd.0014627.ref071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110285","article-title":"A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi","volume":"9","author":"KM Gaskell","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"pntd.0014627.ref072","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi","volume":"50","author":"JC Nussbaum","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pntd.0014627.ref073","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QCO.0b013e32832fa214","article-title":"Treatment of cryptococcal meningitis in resource limited settings","volume":"22","author":"DJ Sloan","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"pntd.0014627.ref074","first-page":"873","article-title":"Present status of nitroxoline","volume":"35","author":"E Bergogne-Berezin","year":"1987","journal-title":"Pathol Biol (Paris)"},{"issue":"2","key":"pntd.0014627.ref075","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bioelechem.2010.08.003","article-title":"Electrochemistry of the antibacterial and antifungal drug nitroxoline and its determination in bulk form, pharmaceutical formulation and human blood","volume":"80","author":"MM Ghoneim","year":"2011","journal-title":"Bioelectrochemistry"},{"issue":"1","key":"pntd.0014627.ref076","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3201\/eid2901.221531","article-title":"Successful treatment of Balamuthia mandrillaris granulomatous amebic encephalitis with nitroxoline","volume":"29","author":"N Spottiswoode","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pntd.0014627.ref077","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/neuonc\/nou139","article-title":"Nitroxoline induces apoptosis and slows glioma growth in vivo","volume":"17","author":"J Lazovic","year":"2015","journal-title":"Neuro Oncol"},{"issue":"1","key":"pntd.0014627.ref078","doi-asserted-by":"crossref","first-page":"2294854","DOI":"10.1080\/22221751.2023.2294854","article-title":"Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition","volume":"13","author":"P He","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"pntd.0014627.ref079","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/17425247.2022.2084530","article-title":"Inhaled antifungal therapy: benefits, challenges, and clinical applications","volume":"19","author":"K Ito","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"issue":"15","key":"pntd.0014627.ref080","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"M Hoenigl","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"pntd.0014627.ref081","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/jof6040373","article-title":"PC945, a novel inhaled antifungal agent, for the treatment of respiratory fungal infections","volume":"6","author":"A Murray","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"pntd.0014627.ref082","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jcf.2013.10.014","article-title":"Nebulized voriconazole in infections with Scedosporium apiospermum--case report and review of the literature","volume":"13","author":"J Holle","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"4","key":"pntd.0014627.ref083","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bcp.14166","article-title":"A phase 1\/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics","volume":"86","author":"DL Hava","year":"2020","journal-title":"Br J Clin Pharmacol"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:23:52Z","timestamp":1786987432000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014627"}},"subtitle":[],"editor":[{"given":"Francelise","family":"Bridi Cavassin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":83,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0014627","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}